Nearly 40% of participants receiving the treatment achieved a clinically meaningful response, according to data released by the biotechnology firm. The drug profile remains well-tolerated, providing a potential alternative to the frequent dosing schedules required by current standard-of-care medications.
In section Market Quotes
Compass Pathways Surges as Depression Drug Trial Meets Key Milestones
Shares of Compass Pathways jumped 8.7% to $13.96 in premarket trading Tuesday, signaling investor confidence after the company reported that its treatment-resistant depression therapy, COMP360, demonstrated both rapid onset and durable effectiveness in its latest clinical trial.
Chief Executive Kabir Nath described the results as a catalyst for a broader shift in mental health treatment. The company is currently preparing a rolling new drug application for the U.S. Food and Drug Administration. If regulatory milestones are met, Compass aims to launch the therapy in the first half of next year.
Comments (0)
No comments yet. Be the first!